liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer
Linköping University, Department of Biomedical Engineering. Linköping University, The Institute of Technology.
Department of Urology, Örebro University Hospital, Örebro.
Department of Urology, Örebro University Hospital, Örebro.
Department of Urology, Örebro University Hospital, Örebro.
Show others and affiliations
2012 (English)In: Scandinavian Journal of Urology and Nephrology, ISSN 0036-5599, E-ISSN 1651-2065, Vol. 46, no 1, 19-25 p.Article in journal (Refereed) Published
Abstract [en]

Objective. This study aimed to develop a probabilistic decision support model to calculate the lifetime incremental cost-effectiveness ratio (ICER) between radical prostatectomy and watchful waiting for different patient groups. Material and methods. A randomized trial (SPCG-4) provided most data for this study. Data on survival, costs and quality of life were inputs in a decision analysis, and a decision support model was developed. The model can generate cost-effectiveness information on subgroups of patients with different characteristics. Results. Age was the most important independent factor explaining cost-effectiveness. The cost-effectiveness value varied from 21 026 Swedish kronor (SEK) to 858 703 SEK for those aged 65 to 75 years, depending on Gleason scores and prostate-specific antigen (PSA) values. Information from the decision support model can support decision makers in judging whether or not radical prostatectomy (RP) should be used to treat a specific patient group. Conclusions. The cost-effectiveness ratio for RP varies with age, Gleason scores, and PSA values. Assuming a threshold value of 200 000 SEK per quality-adjusted life-year (QALY) gained, for patients aged ≤70 years the treatment was always cost-effective, except at age 70, Gleason 0–4 and PSA ≤10. Using the same threshold value at age 75, Gleason 7–9 (regardless of PSA) and Gleason 5–6 (with PSA >20) were cost-effective. Hence, RP was not perceived to be cost-effective in men aged 75 years with low Gleason and low PSA. Higher threshold values for patients with clinically localized prostate cancer could be discussed.

Place, publisher, year, edition, pages
London, UK: Informa Healthcare , 2012. Vol. 46, no 1, 19-25 p.
Keyword [en]
cost-effectiveness, decision support, prostate cancer, radical prostatectomy, randomized trial, watchful waiting
National Category
Medical Engineering
URN: urn:nbn:se:liu:diva-70933DOI: 10.3109/00365599.2011.615759ISI: 000299125800005OAI: diva2:442462
Available from: 2011-09-21 Created: 2011-09-21 Last updated: 2012-02-13

Open Access in DiVA

fulltext(387 kB)383 downloads
File information
File name FULLTEXT01.pdfFile size 387 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Lyth, JohanCarlsson, PerShahsavar, Nosrat
By organisation
Department of Biomedical EngineeringThe Institute of TechnologyHealth Technology Assessment and Health EconomicsFaculty of Health SciencesMedical Informatics
In the same journal
Scandinavian Journal of Urology and Nephrology
Medical Engineering

Search outside of DiVA

GoogleGoogle Scholar
Total: 383 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 561 hits
ReferencesLink to record
Permanent link

Direct link